Eterna Therapeutics Stock Net Asset
| ERNA Stock | USD 2.00 0.03 1.48% |
Eterna Therapeutics fundamentals help investors to digest information that contributes to Eterna Therapeutics' financial success or failures. It also enables traders to predict the movement of Eterna Stock. The fundamental analysis module provides a way to measure Eterna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eterna Therapeutics stock.
Eterna | Net Asset |
Eterna Therapeutics Company Net Asset Analysis
Eterna Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Eterna Therapeutics Net Asset | 49.13 M |
Most of Eterna Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eterna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eterna Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Eterna Therapeutics is extremely important. It helps to project a fair market value of Eterna Stock properly, considering its historical fundamentals such as Net Asset. Since Eterna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eterna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eterna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Eterna Total Assets
Total Assets |
|
Based on the recorded statements, Eterna Therapeutics has a Net Asset of 49.13 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Eterna Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eterna Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics of similar companies.Eterna Therapeutics is currently under evaluation in net asset category among related companies.
Eterna Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Eterna Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eterna Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eterna Therapeutics' value.| Shares | A. Montag & Associates Inc | 2023-12-31 | 70.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 50.0 | Royal Bank Of Canada | 2023-12-31 | 31.0 | Wells Fargo & Co | 2023-12-31 | 28.0 | Group One Trading, Lp | 2023-12-31 | 19.0 | Citigroup Inc | 2023-12-31 | 15.0 | Jpmorgan Chase & Co | 2023-12-31 | 14.0 | Aspire Private Capital, Llc | 2024-03-31 | 10.0 | Nbc Securities Inc | 2024-03-31 | 10.0 | Lake Street Advisors Group, Llc | 2023-12-31 | 521 K | Cypress Point Wealth Management, Llc | 2023-12-31 | 94.4 K |
Eterna Fundamentals
| Return On Equity | -3.02 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (339.12) % | ||||
| Current Valuation | 46.98 M | ||||
| Shares Outstanding | 5.41 M | ||||
| Shares Owned By Insiders | 39.31 % | ||||
| Shares Owned By Institutions | 7.38 % | ||||
| Number Of Shares Shorted | 34.2 K | ||||
| Price To Book | 5.43 X | ||||
| Price To Sales | 178.22 X | ||||
| Revenue | 68 K | ||||
| EBITDA | (19.55 M) | ||||
| Net Income | (21.67 M) | ||||
| Cash And Equivalents | 19.41 M | ||||
| Cash Per Share | 6.60 X | ||||
| Total Debt | 41.84 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (20.41 M) | ||||
| Short Ratio | 6.32 X | ||||
| Earnings Per Share | (4.08) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 3.0 | ||||
| Beta | 8.21 | ||||
| Market Capitalization | 10.98 M | ||||
| Total Asset | 49.13 M | ||||
| Retained Earnings | (186.98 M) | ||||
| Working Capital | 3.03 M | ||||
| Net Asset | 49.13 M |
About Eterna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eterna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Eterna Therapeutics Piotroski F Score and Eterna Therapeutics Altman Z Score analysis. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Eterna Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.08) | Revenue Per Share 0.013 | Return On Assets (0.36) | Return On Equity (3.02) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.